Vaxxas set to develop Nanopatch 'needle-free' vaccines

Vaxxas said this week that it has raised $20 million for a series of clinical programs toward development of a line of vaccine products using the company's Nanopatch platform, which utilizes painless microneedles.

"As we have advanced the development of our Nanopatch needle-free vaccination technology, we have seen tremendous opportunities to create our own proprietary pipeline of Nanopatch-based vaccine products, as well as those with partners," Vaxxas President and CEO David Hoey said.

During pre-clinical studies, Nanopatch, which was pioneered by Mark Kendall's research group at the Australian Institute of Bioengineering and Nanotechnology at the University of Queensland in Brisbane, was found to give the same protection as traditional injected vaccines, but at 1/100th of the dose. Nanopatch utilizes microneedles that are dry-coated with the vaccine and are painless.

Nanopatch vaccines certainly have a large market potential and may one day challenge their needle-and-syringe counterparts. Nanopatch doses not only are smaller, but also do not require refrigeration during storage and transportation.

Back in 2012, Vaxxas partnered with Merck to develop the Nanopatch platform. This allowed Merck to evaluate, develop and commercialize Nanopatch with an undisclosed vaccine.

Organizations in this Story


Want to get notified whenever we write about Vaxxas ?
Next time we write about Vaxxas, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.